Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
27-29 January, 2026
Not Confirmed
Not Confirmed
27-28 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
27-29 January, 2026
Industry Trade Show
Not Confirmed
27-28 January, 2026
Digital content

20 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/20/3221555/0/en/BioXcel-Therapeutics-Submits-Supplemental-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-IGALMI-Label-Expansion-in-the-At-Home-Setting.html

03 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/03/3198737/0/en/Award-Winning-Journalist-Anjalee-Khemlani-to-Host-Virtual-Roundtable-with-Leading-Medical-Experts-to-Discuss-Latest-Developments-in-Treating-Acute-Agitation-Related-to-Neuropsychia.html

14 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/14/3166033/0/en/BioXcel-Therapeutics-Announces-Positive-Results-from-Correlation-Study-Supporting-SERENITY-At-Home-Exploratory-Efficacy-Outcomes.html

13 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/13/3165413/0/en/BioXcel-Therapeutics-to-Ring-Nasdaq-Closing-Bell-on-October-14-to-Celebrate-a-Transformative-Milestone-in-Neuroscience-Innovation.html

18 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/18/3152274/0/en/BioXcel-Therapeutics-Regains-Compliance-with-Nasdaq-Market-Value-of-Listed-Securities-Requirements.html

10 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/10/3147596/0/en/BioXcel-Therapeutics-Reports-Positive-Topline-Exploratory-Efficacy-Data-from-SERENITY-At-Home-Pivotal-Phase-3-Safety-Trial-for-Agitation-Associated-with-Bipolar-Disorders-or-Schizo.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE